Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Education » AGITG Annual Scientific Meeting

AGITG Annual Scientific Meeting

  • August 29, 2019

Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting (ASM), Adelaide Convention Centre 21 -23 August 2019 

Report by Meredith Cummins

The AGITG Annual Scientific Meeting was very well attended in Adelaide 21 – 23 August with 350 delegates registered. This meeting is a wonderful opportunity for health care professionals internationally and globally to network and work collaboratively to improve cancer treatments. Prof Tim Price, Chair of AGITG has stated that “Cancer treatment advances are only as good as patients’ ability to access them. But for far too many patients, high quality cancer care and clinical trials are out of reach. We have much work to do before everyone with cancer has equal access to the best treatments and the opportunity to participate in research.” By working together as a community, Professor Price emphasised that we can find solutions that will help ensure that the advances needed can be achieved.” This encompasses the work of the AGITG.

The opening plenary session was Rare cancers, how can we do it better? The presentations were by guest international speakers Professor Christian Jobin (United States) who discussed “The large fingerprint of Intestinal Microbiota in cancer”, Professor Stephen J Wigmore (United Kingdom) “State of the Art Biliary Tract Cancers and Associate Professor Manisha Palta (United States) “combination of Radiation and Immunotherapy: Fact or Fiction. These topics, especially Microbiota whereby samples of gastrointestinal bacteria (stool) investigate the role of bacteria in cancer, created much discussion and were the focus of further sessions throughout the meeting.

Other international invited faculty were Professor James L. Abbruzzese (United States), Professor Sharon Gil (Canada) and Professor Florian Lordick (Germany).

On the Wednesday afternoon a multidisciplinary workshop was held which included management of operational pancreatic tumours. Neoadjuvant therapy and nutritional care. The Thursday afternoon session of New Concepts Symposium saw four concepts presented to the audience which then were voted upon as to whether to take the concept further. One of the presented concepts presented by Dr Mark McGregor was a Phase II study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose Bengal disodium in combination with Pembrolizumab – was given the best new concept  award. A/Prof Michael Michael also presented during the ASM the new concept study LuCAT.

On Friday morning AGITG Upper GI Cancer trials were presented including Control NETs by A/Prof David Wyld (Capecitabine ON Temazolamide Radionuclide therapy Octreotate Lutetium-177 Neuroendocine tumours study) which has closed to recruitment and, NABNEC by A/Prof Mustafa Khasraw (A Randomised Phase II Study of Nabpacitaxel in Combination with Carboplatin as first line Treatment of Gastrointestinal Neuroendocrine Carcinomas) which is still open to recruitment.

It was fabulous to participate in this meeting. Throughout the meeting the Unicorn Foundation was gratefully acknowledged for the ongoing funding for many NET trials which is vital to the advances in NET management.

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

5HIAA Urine Collection Instructions for Patients

June 23, 2022

Donor Report 2021/2022

June 21, 2022

Cancer Nurses Society of Australia 24th Annual Congress

June 18, 2022

The Future of Precision Oncology in Nuclear Medicine – Report

June 16, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousVideo to help pronounce “Neuroendocrine”
NextBrisbane NET Patient ForumNext

Related Posts

5HIAA Urine Collection Instructions for Patients

Your doctor may order you to do a 5HIAA 24 hour urine test. Please click below to see the downloadable instruction sheet. Previously there were

Donor Report 2021/2022

It is with heartfelt gratitude that we thank our kind donors who enable us to continue to do what we do. We encourage you to

Cancer Nurses Society of Australia 24th Annual Congress

The 24th Cancer Nurses Society of Australia’s  (CNSA) Annual Congress took place at Brisbane Convention Centre Thursday 16 June to Saturday 18 June 2022. The

The Future of Precision Oncology in Nuclear Medicine – Report

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies
Menu
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
Menu
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
Menu
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
Menu
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative